Veterinary Medicines: Northern Ireland

Emma Hardy Excerpts

Wednesday 3rd December 2025 Westminster Hall

[The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Emma Hardy)]

It is such a pleasure to serve under your chairwomanship, Dr Allin-Khan, and to respond to the debate. I thank the hon. Member for South Antrim (Robin Swann) for securing this debate on a highly important matter and for his continued commitment to the veterinary medicine supply in Northern Ireland. He might have noticed I am not the farming Minister, but I am pleased to be here to respond on her behalf.

I recognise how important this issue is to the people of Northern Ireland and all the communities the hon. Gentleman represents. He has raised many important issues with me today; I will endeavour to address as many as possible. Baroness Hayman was in Northern Ireland just last week meeting the hon. Gentleman and many of our organisations. She met vets, the Minister of Agriculture, Environment and Rural Affairs, the permanent secretary, and the Northern Ireland Business Brexit Working Group to demonstrate how important the issue is to the UK Government. Those channels of dialogue remain open.

I thank industry stakeholders for their ongoing support and work to make the changes necessary to continue supply to Northern Ireland. We have done extensive work with industry, which has given us the confidence in the arrangements we have put in place to manage a smooth transition into 2026. Before responding to specific questions raised in the debate, I want first to outline the Government’s view on veterinary medicine in Northern Ireland.

Safeguarding the supply of veterinary medicine in Northern Ireland after the grace period ends remains a core Government priority. We are committed to ensuring that the health and welfare of all animals is maintained in all circumstances. We are aware of concerns raised about pack size, discontinued products and the potential for increased costs, and we take those concerns extremely seriously. We have engaged extensively with stakeholders on those issues. Based on the evidence available to us through this engagement, our view remains that disruption at the end of the grace period will be limited and the arrangements we have in place will manage supply into 2026.

[Gavin Robinson]

I am grateful to the Minister for taking the intervention. Does she accept that the fundamental flaw in the Government’s approach is to accept the premise that the European Union controls what access there should be from one part of our United Kingdom to another and that we are accepting that there should be a chink in the UK internal market? Does she understand that when the grace period comes to an end, the European Union cannot and will not be able to demonstrate any detriment to their single market because of the ongoing availability until the end of this year. There has not been any detriment to their single market because of the availability of veterinary medicines from GB to Northern Ireland; and nor will there be, so all this is wholly disproportionate and unnecessary.

[Emma Hardy]

I thank the right hon. Member. He will recognise that it is important for the UK to be legally compliant with all of our international agreements. We take seriously the Windsor framework and the rules that it gave our country. I would not want to be part of a Government who disregard international agreements, but I completely understand his concerns around veterinary medicines.

We expect 10% to 15% of currently licensed veterinary medicines in Northern Ireland to be discontinued, but most are either dormant and not sold in Northern Ireland or have multiple alternatives available. We have analysed each discontinuation against multiple criteria to determine the position. However, we appreciate we can never have perfect data and that situations change. That is why we have also announced the veterinary medicines internal market scheme and the veterinary medicine health situation scheme: to help to address any gaps, should they arise.

The veterinary medicines internal market scheme removes administrative burdens from vets moving medicine that are not vaccines from Great Britain to Northern Ireland when, in their clinical judgment, that is needed. It is based on the existing cascade procedure, with which vets are very familiar. These simplifications allow the scheme to be as responsible as possible when managing supply issues.

The veterinary medicine health situation scheme allows the Government to temporarily authorise an alternative medicine when a discontinuation is expected to lead to a health situation. It is designed to provide a dedicated supply mechanism to address supply issues, should they arise.

[Jim Allister]

Sadly, we live under EU law, and the EU law that governs these matters says that only where there is exceptional breakdown can there be alternative arrangements. Have the Government obtained permission from their EU masters for the two schemes to which the Minister refers? According to the Government, they are going to be routine, rather than for exceptional breakdowns.

[Emma Hardy]

I thank the hon. and learned Gentleman; of course, I reject the phrase “EU masters”. These schemes are really important to make sure that the vets or those who require the medicine have the medicine that they need in Northern Ireland.

I want to take this opportunity to make a few further remarks about our assessment on discontinuations. In June, the Government said that “fewer than 20 products” are expected to be discontinued where there was risk of “significant adverse impacts” if not addressed through our schemes. I am pleased to announce that further analysis has reduced that figure to six. Following extensive engagement and detailed analysis, we are now satisfied that none of these discontinuations would lead to a health situation or other significant adverse impacts.

In some cases, the products will no longer be discontinued; in others, there are sufficient alternatives available in Northern Ireland or from the EU. However, we will of course continue to monitor the list and any new discontinuations, and we welcome stakeholder feedback. On divergence, the veterinary medicines regulations for Great Britain were updated in 2024 to reflect the comparable EU regulations 2019/6 and 2019/4, thereby basically bringing Great Britain and Northern Ireland into closer alignment.

These are the regulations that will apply in Northern Ireland from the end of the grace period. Divergence between Great Britain and Northern Ireland veterinary medicine regulation is minimal, and is something that the Veterinary Medicines Directorate monitors closely in considering where alignment may be beneficial.

I will now address some of the other concerns raised. We have heard that stakeholders are concerned about insufficient pack sizes being available and about that leading to cost increases and issues with dispensing veterinary medicines. However, based on our extensive engagement, we have no evidence that pack size changes are a systematic issue. Where pack size changes occur, we expect the most popular sizes to remain, but of course, if the situation changes or if new evidence comes to light, we will look to use the schemes we have in place.

More broadly on costs, we have had positive reassurance from a number of pharmaceutical companies that they will not increase prices, but we will closely monitor the situation into 2026.

[Robin Swann]

With regard to market surveillance to look at costs, what powers do the Government have, should a pharmaceutical supplier decide to increase costs? That would be interfering with the commercial market, and I do not see where the Government have the powers to do what they say they want to do, or may do, in that instance.

[Emma Hardy]

The hon. Gentleman raises an important point. We would of course look at whatever powers we have at our disposal, but as a Government we do not want to see costs unfairly increased for Northern Ireland customers. That is the important principle that we are trying to address by doing this. We hope that that will not be the case, but if it is, we would need to work closely and carefully with all stakeholders in Northern Ireland, and we would of course follow up with meetings with representatives from Northern Ireland about that.

We are not complacent. The Government’s position is based on our assessment of the best possible evidence available, and we take stakeholder concern extremely seriously. As I mentioned at the beginning, Baroness Hayman was in Northern Ireland just last week for a couple of days, meeting with people about this very issue. I know that it is something she cares about and sees as incredibly important.

Our view is based on what we can see. The transition to new arrangements at the end of the year will be manageable, but if there are unexpected problems, we have our two schemes to manage that. I also note that there will not be a cliff edge on supply at the end of the year. All medicines supplied to Northern Ireland before the end of this year will remain available, and some of those products have long shelf lives. We have advised businesses to take prudent action, but that is just in case. We have put in many different mitigations to try and resolve this issue. We will continue to monitor the situation closely, and we will respond rapidly if issues arise. As I mentioned at the beginning of my speech, we want to continue and maintain open dialogue with all representatives.

[Robin Swann]

The Minister has been gracious in taking interventions. One issue that she has not touched on yet is pet owners with a prescription who buy medication online from GB suppliers. What reassurance can she give us there? I have heard everything that she has said to date, but I have not heard her address that issue.

[Emma Hardy]

Through our engagement, we are aware of multiple companies that are either being established in Northern Ireland or planning to set up as online retailers there. That is expected to ensure that medicines will remain available through online channels. The Government appreciate that access to online retailers for pet owners to obtain veterinary medicines for their pets is of great importance, so this is something we are monitoring closely. Of course, it would be a positive outcome if those companies were setting up as online retailers in Northern Ireland. As a pet owner myself, I recognise how important it is for pet owners to be able to get the medication their beloved pets need.

We will continue to monitor the situation closely and will respond rapidly. We welcome feedback from stakeholders on specific issues and will continue to work with industry as we have done.

[Carla Lockhart]

Forgive us for not looking at this through the rose-tinted glasses that the Minister has presented today. I feel that what we have heard is another Minister with their head in the sand, utterly tone deaf to what industry, manufacturers and distributors are saying in the public domain. They have put their heads above the parapet. Will the Minister today commit to publishing the list? No one has seen it or has any understanding of it. Will the Minister actually engage with those industry leaders and not just the Department in Northern Ireland, which also seems to have its head in the sand? These industry leaders are saying that we will be at crisis point come the end of this year.

[Emma Hardy]

With respect to the hon. Lady, I refute the idea that this Government have their head in the sand. If we had, we would not have just sent a Minister, Baroness Hayman, to Northern Ireland for two days to meet with everybody there and speak to them, and maintain the extensive engagement that we have. I completely recognise that this is an issue that the hon. Lady is concerned about, and I know how important it is to her. I do not want to be seen to not be taking it seriously, when we absolutely are taking it seriously. As I have tried to outline—because I know that this is an important issue—if there are things about which the hon. Lady remains concerned after the transition period ends in 2026, then the door is open to continue those conversations.

[Carla Lockhart]

Will the Minister give way?

[Emma Hardy]

I will just answer the hon. Lady about the list and then I will.

As to why the list has not been published, it is because of commercial confidentiality. We are unable to share businesses’ supply intentions. Businesses are increasingly providing clarity to their customers, and we encourage those who have not done so to do so.

[Carla Lockhart]

The Minister just talked about what to do if I need to continue to raise my concerns. We need the message to go back very clearly that there has been a veterinary medicines working group and it has been absolutely useless when it comes to raising concerns. No concerns are taken on board by the very same Minister who this Minister just said went to Northern Ireland in the last few days. They have listened but not acted. There is no mechanism to raise concerns or for them to be taken seriously.

[Emma Hardy]

I hold the Minister, Baroness Hayman, in the highest of regard, and I am sure that she is doing absolutely everything she can to listen carefully to concerns and will continue to do so.

I thank the hon. Member for South Antrim for securing this debate and allowing us to discuss the importance of medicine in Northern Ireland. Let us continue to discuss this and continue to talk if any issues are raised. I hope that will not be the case, but if issues are raised, let us work together on that as representatives of our fantastic United Kingdom.

Question put and agreed to.